|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Technical Developments |
1 From the Departments of Radiology (T.B., L.J., A.E., A.H., H.A.) and Cardiology (G.W.), University Hospital, S-751 85 Uppsala, Sweden; and Nycomed Amersham Imaging, Oslo, Norway (L.J.). Received January 3, 2001; revision requested February 14; revision received April 24; accepted May 21. Supported in part by Nycomed Amersham Imaging and Swedish Medical Research Council project 6676. Address correspondence to T.B. (e-mail: Tomas.Bjerner@radiol.uu.se).
The authors evaluated the feasibility of combining single-shot T2-weighted turbo spin-echo magnetic resonance (MR) imaging and first-pass myocardial perfusion MR imaging with an intravascular ultrasmall superparamagnetic iron oxide (USPIO) contrast agent, NC100150 Injection (3 mg of iron per kilogram of body weight). Eight patients with coronary vessel disease underwent T2-weighted turbo spin-echo MR imaging (in-plane resolution, 12 mm) during the first pass of the USPIO contrast agent. The mean decrease in signal intensity in myocardium perfused by a nonstenotic coronary artery was 59% ± 13 (SD) (P < .012) This method is feasible for imaging of myocardial perfusion.
Index terms: Heart, perfusion, 511.12144 Magnetic resonance (MR), contrast enhancement, 511.12143 Myocardium, blood supply, 511.76, 511.771 Myocardium, MR, 511.121412
This article has been cited by other articles:
![]() |
A R Padhani MRI for assessing antivascular cancer treatments Br. J. Radiol., December 1, 2003; 76(suppl_1): S60 - S80. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |